Interindividual variability of drug transporters: Impact on opioid treatment in chronic renal failure

European Journal of Pain Supplements

Volumn 3, Issue 2, 2009, Pages 21-28

  Ranzani, Guglielmina Nadia ^a   De Gregori, Simona ^b   De Gregori, Manuela ^a   Regazzi, Mario ^b   Govoni, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chronic renal failure; Dialysis; Opioids; Polymorphism; Transporters

Indexed keywords

ABC TRANSPORTER; ALFENTANIL; ANTICONVULSIVE AGENT; BUPRENORPHINE; FENTANYL; GLYCOPROTEIN P; HYDROMORPHONE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NALOXONE; OPIATE; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER; OXYCODONE; PRAVASTATIN; TORASEMIDE;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CANCER PAIN; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; DRUG TREATMENT FAILURE; EPILEPSY; GENETIC VARIABILITY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MEMBRANE TRANSPORT; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION;

EID: 70350499866     PISSN: 17543207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eujps.2009.07.010     Document Type: Article

References (47)

1. Abdel-Razzak Z., Loyer P., Fautrel A., Gautier J.C., Corcos L., Turlin B., et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44 (1993) 707-715
2. Akahoshi T., Kobayashi N., Hosaka S., Sekiyama N., Wada C., and Kondo H. In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 10 (1995) 2244-2249
3. Bistrian B.R. Role of the systemic inflammatory response syndrome in the development of protein-calorie malnutrition in ESRD. Am J Kidney Dis 32 4 (1998) S113-S117
4. Böger Rainer H. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliative Med 20 (2006) s17-s23
5. Christrup L.L. Morphine metabolites. Acta Anaes Scand 41 (1997) 116-122
6. Coller J.K., Barratt D.T., Dahlen K., Loennechen M.H., and Somogyi A.A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80 6 (2006) 682-690
7. Crettol S., Déglon J.J., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80 6 (2006) 668-681
8. Dietrich C.G., Geier A., and Oude Elferink R.P.J. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 (2003) 1788-1795
9. Dreisbach A.W., and Lertora J.J. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 16 (2003) 45-50
10. Eija K. How different is oxycodone from morphine?. Pain 132 (2007) 227-228
11. Elkiweri I.A., Yan Ling Z., Ka-Yun N., Uwe C., Martha C.T.v.P., and Thomas K.H. Protein transporters differentially mediate opioid pharmacodynamics as measured by continuous electroencephalogram. FASEB J 21 (2007) 889-893
12. Elkiweri I.A., Yan Ling Z., Uwe C., Ka-Yun N., Martha C.T.v.P., and Thomas K.H. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Anal 108 1 (2009) 149-159
13. Eveline L.A.v.D., Raymonda R., Elise S., Bovill J.G., and Albert D. Morphine-6-glucuronide: morphine's successor for postoperative pain relief?. Anesth Analg 102 (2006) 1789-1797
14. Flitz J., Norbert G., Reinhard S., Rudi L., Jürgen S., and Wolfang K. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 10 8 (2006) 743-748
15. Gertrude Andersen, Lona Christrup, Per Sjǿgren. Relationship among morphine metabolism, pain and side effects during long term treatment: an update. 2003;25(1):74-91.
16. Higuchi T., Yamamoto C., Kuno T., Mizuno M., Takahashi S., and Kanmatsuse K. Increased production of interleukin-1beta and interleukin-1 receptor antagonist by peripheral blood mononuclear cells in undialyzed chronic renal failure. Nephron 76 (1997) 26-31
17. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 7 (2000) 3473-3478
18. Kim R.B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33 2 (2003) 1-5
19. König J., Seithel A., Gradhand U., and Fromm M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372 6 (2006) 432-443
20. Maeda K., and Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23 4 (2008) 223-235
21. Marvyn D. Opioids in renal failure and dialysis patients. J Pain Symp Manag 28 5 (2004) 497-504
22. Matzke G.R., and Frye R.F. Drug administration in patients with renal insufficiency: minimising renal and extrarenal toxicity. Drug Saf 16 (1997) 205-231
23. Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M., et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13 (2002) 866-874
24. Naud J., Josée M., Francois A.L., Stéphane L., Alain B., and Vincent P. Effects of chronic renal failure on liver drug transporters. Drug Met Dispos 36 (2008) 124-128
25. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., et al. Polymorphisms of OATP-C (SLC21A6) and OAT 3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73 6 (2003) 554-565
26. Nolin T.D., Frye R.F., and Matzke G.R. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42 (2003) 906-925
27. Oettinger C.W., Bland L.A., Oliver J.C., Arduino M.J., McAllister S.K., and Favero M.S. The effect of uremia on tumor necrosis factor-alpha release after an in vitro whole-blood endotoxin challenge. J Am Soc Nephrol 4 (1994) 1890-1895
28. Pichette V., and Leblond F.A. Drug metabolism in chronic renal failure. Curr Drug Metab 4 (2003) 91-103
29. Pöyhia R., Seppala T., Olkkola K.T., and Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33 (1992) 617-621
30. Sarhill N., Declan W., and Kristine A.N. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 9 (2001) 84-96
31. Säwe J., and Odar-Cederlöf. Kinetics of morphine in patients with renal failure. Eur J Pharmacol 32 (1987) 377-382
32. Sesaki S. Molecular basis of organic anion and cation transport. Kidney Int 57 (2000) 1772-1773
33. Somogyi A., Daniel T.B., and Janet K.C. Pharmacogenetics of opioids. Clin Pharmac Ther 81 3 (2007) 429-572
34. Štefkovà J., Poledne R., and Hubáček J.A. ATP-Binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res 53 (2004) 235-243
35. Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 (1999) 1899-1911
36. Sun H., Frassetto L., and Benet L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109 (2006) 1-11
37. Sunder-Plassmann G., Kapiotis S., Gasche C., and Klaar U. Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int 45 (1994) 1484-1488
38. Susan L.M., Christopher W.C., Hazem H., Natalie D.E., and Andrew C. Opioids and efflux transporters. 1. P-Glycoprotein substrate activity of N-substituted analogs of meperidine. Bioorg Med Chem Lett 17 5 (2007) 1160-1162
39. Sweeney B.P., and Grayling M. Opioids, transporters and the blood-brain barrier. Eur J Anesth 22 (2005) 489-491
40. Tomoe F., Thomas J.U., Maja K.L., Kazumi F., and Kathleen M.G. Transport of drugs in the kidney by the Human Organic Cation Transporter, OCT 2 and its genetic variants. J Pharm Sci 95 1 (2006) 25-36
41. Touchette M.A., and Slaughter R.L. The effect of renal failure on hepatic drug clearance. DICP 25 (1991) 1214-1224
42. Ufer M., Mosyagin I., Muhle H., Jacobsen T., Haenisch S., Häsler R., et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 19 5 (2009) 353-362
43. Uwe C., Tobin S., Yan Ling Z., Wolfang S., Volker S., Saskia T., et al. Active drug transport of immunosuppressants. New insights for pharmacokinetics and pharmacodynamics. Drug Mon 28 1 (2006) 39-44
44. Vania P., Shirley T., and Micheline P.-M. Regulation of drug transporters during infection and inflammation. Mol. Interventions 7 2 (2007) 99-111
45. Vormfelde S.V., Schirmer M., Hagos Y., Toliat M.R., Engelhardt S., Meineke I., et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 62 3 (2006) 323-335
46. Wandel C., kim R., and Wood M. Interaction of Morphine, Fentanyl, Sufentanyl, Alfentanyl and Loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96 4 (2002) 913-920
47. Ziesche R., Roth M., Papakonstantinou E., Nauck M., Horl W.H., Kashgarian M., et al. A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 91 (1994) 301-305